



Dkt. 41426-GC/JPW/MAF/AJD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ron. S. Israeli et al.

U.S. Serial No.: 10/614,625

Group Art Unit:

Filed: July 2, 2003

Examiner:

For: PROSTATE-SPECIFIC MEMBRANE ANTIGEN

1185 Avenue of the Americas  
New York, New York 10036  
March 26, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Supplemental Information Disclosure Statement is submitted under 37 C.F.R. §1.97(b)(3) to supplement the Information Disclosure Statement filed on July 2, 2003 in connection with the above-identified application.

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references which are listed on the attached PTO-1449 form (**Exhibit A**).

1. U.S. Patent No. 4,554,101, issued November 19, 1985 to Thomas P. Hopp;
2. U.S. Patent No. 5,162,504, issued November 10, 1992 to Julius S. Horoszewicz;
3. U.S. Patent No. 5,538,866, issued July 23, 1996 to Israeli et al.;
4. PCT International Application No. PCT/US93/10624, filed November 5, 1993, International Publication No. WO 94/09820, published May 11, 1994;
5. Abdel-Nabi, H., Wright, G.L., Gulfo, J.V., Petrylak, D.P., Neal, C.E. et al. (1992) Monoclonal Antibodies and

- Radioimmunoconjugates in the Diagnosis and Treatment of Prostate Cancer, *Semin. Urol.* 10: 45-54;
6. Axelrod, H.R. et al. (1992) Preclinical results and human immunohistochemical studies with <sup>90</sup>Y-CYT-356. A new prostate cancer therapeutic agent, *Abstract 596. AUA 87th Annual Meeting*, May 10-14, 1992, Washington, D.C.;
  7. Carter, B.H. and Coffey, D.S. (1990) The Prostate: An Increasing Medical Problem, *The Prostate* 16: 39-48;
  8. Chang, C.S., Kokontis, J. and Liao, S.T. (1988) Structural Analysis of Complementary DNA and Amino Acid Sequences of Human and Rat Androgen Receptors, *Proc. Natl. Acad. Sci. USA* 85: 7211-7215;
  9. Corr, J.G. et al. (1994) Prostate Specific Membrane Antigen (PSM) Expression in Orthotopically Implanted Human Prostate Cancer Cells in Nude Mice Slows Tumor Growth and Metastatic Potential, *J. Urol.* 151: 492A;
  10. Culver, K.W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E.H. and Blaese, R.M. (1992) In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors, *Science* 256: 1150-1152;
  11. Decensi, A., Guarneri, D., Paoletti, M.C., Lalanne, J.M., Merlo, F. and Boccardo, F. (1991) Phase II Study of the Pure Non-steroidal Antiandrogen Nilutamide in Prostatic Cancer, *Eur. J. Cancer* 27: 1100-1104;
  12. Faber, P.W., van Rooij, H.C., van der Korput, H.A., Baarends, W.M., Brinkmann, A.O., Grootegeod, J.A. and Trapman, J. (1991) Characterization of the Human Androgen Transcription Unit, *J. Biol. Chem.* 266: 10743-10749;
  13. Feng, Q. et al. (1991) Purification and Biochemical Characterization of the 7E11-C5 Prostate Carcinoma-Associated Antigen, *Proc. Am. Assoc. Cancer Res.* 32: 239;
  14. Fey, M.F., Kulozik, A.E., Hansen-Hagge, T.E. and Tobler, A. (1991) The Polymerase Chain Reaction: A New Tool for the

- Detection of Minimal Residual Disease in Haematological Malignancies, *Eur. J. Cancer* 27: 89-94;
15. Henttu, P. and Vihko, P. (1989) cDNA Coding for the Entire Human Prostate Specific Antigen Shows High Homologies to the Human Tissue Kallikrein Genes, *Biochem. Biophys. Res. Commun.* 160: 903-910;
  16. Horoszewicz, J.S., Kawinski, E. and Murphy, G.P. (1987) Monoclonal Antibodies to a New Antigen Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients, *AntiCancer Res.* 7: 927-936;
  17. Huber, B.E., Richards, C.A. and Krenitsky, T.A. (1991) Retroviral-mediated Gene Therapy for the Treatment of Hepatocellular Carcinoma: An Innovative Approach for Cancer Therapy, *Proc. Natl. Acad. Sci. USA* 88:8039-8043;
  18. Israeli, R.S. et al., (1992) Purification and Molecular Cloning of a New Prostate-Specific Antigen, *Cancer Res.* 33: 356;
  19. Israeli, R.S., Powell, C.T., Fair, W.R. and Heston, W.D. (1993) Molecular Cloning of a Complementary DNA Encoding a Prostate-specific Membrane Antigen, *Cancer Res.* 53: 227-230;
  20. Israeli, R.S. et al. (1993) Molecular Cloning and Characterization of a Prostate-Specific Membrane Antigen, *J. Urol.* 149: 471A;
  21. Israeli, R.S. et al. (1993) Characterization of the Prostate-Specific Membrane Antigen (PSM), *Proc. Am. Assoc. Cancer Res.* 34: 255;
  22. Israeli, R.S., Powell, C.T., Corr, J.G., Fair, W.R. and Heston, W.D. (1994) Expression of the Prostate Specific Membrane Antigen, *Cancer Res.* 54: 1807-1811;
  23. Israeli, R.S., Miller, W.H. Jr., Su, S.L., Powell, C.T., Fair, W.R. et al. (1994) Sensitive Nested Reverse Transcription Polymerase Chain Reaction Detection of

- Circulating Prostatic Tumor Cells: Comparison of Prostate-specific Membrane Antigen and Prostate-specific Antigen-based Assays, *Cancer Research* 54: 6306-6310;
24. Israeli, R.S. et al. (1994) Localization of the Prostate Specific Membrane Antigen (PSM) to the Putative Metastasis-Suppressor Region on Human Chromosome 11, *J. Urol.* 151: 252A;
  25. Israeli, R.S. et al., (1994) Sensitive Detection of Prostatic Hematogenous Micro-Metastases Using Prostate Specific Antigen (PSA) And Prostate Specific Membrane Antigen (PSM) Derived Primers in the Polymerase Chain Reaction (PCR), *J. Urol.* 151: 373A;
  26. Israeli, R.S. et al. (1994) Localization of the Prostate Specific Membrane Antigen (PSM) to the Putative Metastasis-Suppressor Region on Human Chromosome 11, *Proc. Am. Assoc. Cancer Res.* 35: 271;
  27. Keer, H.N., Kozlowski, J.M., Tsai, Y.C., Lee, C., McEwan, R.N. and Grayhack, J.T. (1990) Elevated Transferrin Receptor Content in Human Prostate Cancer Cell Lines Assessed In Vitro and In Vivo, *J. Urol.* 143: 381-385;
  28. Lopes, A. D. et al. (1993) Immunohistochemical and Pharmacokinetic Characterization of the Site-specific Immunoconjugate CYT-356 Derived from Antiprostate Monoclonal Antibody, *Cancer Res.* 50: 6423-6429;
  29. Lubahn, D.B., Brown, T.R., Simental, J.A., Higgs, H.N., Migeon, C.J., Wilson, E.M. and French, F.S. (1989) Sequence of the Intron/exon Junctions of the Coding Region of the Human Androgen Receptor Gene and Identification of a Point Mutation in a family with Complete Androgen Insensitivity, *Proc. Natl. Acad. Sci. USA* 86: 9534-9538;
  30. Lundwall, A, and Lilja, H. (1987) Molecular Cloning of Human Prostate Specific Antigen cDNA, *FEBS Lettr.* 214: 317-322;

31. Mukhopadhyay, T., Tainsky, M., Cavender, A.C. and Roth, J.A. (1991) Specific Inhibition of K-ras Expression and Tumorigenicity of Lung Cancer Cells by Antisense RNA<sup>1</sup>, *Cancer Res.* 51: 1744-1748;
32. Riegman, P.H.J. et al. (1989) The Prostate-Specific Antigen Gene and the Human Glandular Kallikrein-1 Gene are Tandemly Located on Chromosome 19, *FEBS Lettr.* 247: 123-126;
33. Sharief, F.S., Lee, H., Leuderman, M.M., Lundwall, A., Deaven, L.L., Lee, C.L. and Li, S.S. (1989) Human prostatic acid phosphatase: cDNA cloning, gene mapping and protein sequence homology with lysosomal acid phosphatase. *Biochem. Biophys. Res. Commun.* 160: 79-86;
34. Solin, T., Kontturi, M., Pohlmann, R. and Vihko, P. (1990) Gene Expression and Prostate Specificity of Human Prostatic Acid Phosphatase (PAP): Evaluation By RNA Blot Analyses, *Biochem. Biophys. Acta* 1048: 72-77;
35. Su, S.L., et al. (1994) Sensitive Detection of Prostatic Hematogenous Micrometastases Using Prostate Specific Antigen (PSA) and Prostate Specific Membrane Antigen (PSM) Derived Parameters in the Polymerase Chain Reaction, *Proc. Am. Assoc. Cancer Res.* 35: 271;
36. Troyer, John K. (1994) Biochemical Characterization and Mapping of the 7E11-C5.3 Epitope of the Prostate Specific Membrane Antigen (PSMA), *Basic and Clinical Aspects of Prostate Cancer: Abstract C38*;
37. Vihko, P., Virkkunen, P., Henttu, P., Roiko, K., Solin, T. and Huhtala, M.L. (1988) Molecular Cloning and Sequence Analysis of cDNA Encoding Human Prostatic Acid Phosphatase, *FEBS Lettr.* 236: 275-281;
38. Vile, R.G. and Hart, I.R. (1993) In Vitro and In Vivo Targeting of Gene Expression to Melanoma Cells, *Cancer Res.* 53: 962-967;
39. Waibel, R. et al. (1990) Therapy of Small Cell Lung Cancer

- Xenografts in a Nude Mouse model: Evaluation of Radioimmunotherapy and Immunotoxin Therapy, *Antibody Immunoconjugates and Radiopharmaceuticals* 34: 54;
40. Watt, K.W.K. et al. (1986) Human Prostate-Specific Antigen: Structural and Functional Similarity with Serine Proteases, *Proc. Natl. Acad. Sci. USA* 83: 3166-3170;
  41. Wright, Jr., G.L, Feng, Q., Beckett, M.L., Lopes, D. and Gilman, S.C. (1990) Characterization of a new prostate carcinoma-associated marker: 7E11-C5. *Antibody, Immunoconjugates and Radiopharmaceuticals* 3: 89 (Abstract 193);
  42. Young, R.A. and Davis, R.W. (1983) Efficient Isolation of Genes by Using Antibody Probes, *Proc. Natl. Acad. Sci. USA* 80: 1194-1198;
  43. U.S. Patent No. 5,153,118, issued October 6, 1992 to George L. Wright, Jr. and James J. Starling;
  44. U.S. Patent No. 5,852,167, issued December 22, 1998 to Brian K. Kay and Nils B. Adey;
  45. U.S. Patent No. 5,939,258, issued August 17, 1999 to Carlo Croce et al.;
  46. U.S. Patent No. 6,107,090, issued to Neil H. Bander on August 22, 2000;
  47. PCT International Application No. PCT/US97/05214, filed March 25, 1997, International Publication No. WO 97/35616, published October 2, 1997;
  48. PCT International Application No. PCT/US99/05864, filed March 18, 1999, International Publication No. WO 99/47554, published September 23, 1999;
  49. U.S. Patent No. 6,136,311, issued October 24, 2000 to Neil H. Bander;
  50. U.S. Patent No. 6,150,508, issued November 21, 2000 to Murphy et al.;
  51. Su, S.L., Huang, I.P., Fair, W.R., Powell, C.T. and Heston,

- W.D. (1995) *Cancer Res.*, 55: 1441-1443;
52. Bowie, J.U., Reidhaar-Olson, J.F., Lim, W.A. and Sauer, R.T. (1990) Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions, *Science* 147: 1306-1310;
53. Kumar, V., Urban, J.L., Horvath, S.J. and Hood, L. (1990) Amino Acid Variations at a Single Residue in an Autoimmune Peptide Profoundly Affect Its Properties: T-Cell Activation, Major Histocompatibility Complex Binding, and Ability to Block Experimental Allergic Encephalomyelitis, *Proc. Natl. Acad. Sci. USA* 87: 1337-1341;
54. Lazar, E., Watanabe, S., Dalton, S. and Sporn, M.B. (1988) Transforming Growth Factor  $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, *Mol. Cell Biol.* 8: 1247-1252;
55. EPO International Publication No. EP 0 173 951, published December 3, 1986;
56. Translation of the Abstract of EP 0 173 951, i.e., Reference 55;
57. Gately, M.K., Wolitzky, A.G., Quinn, P.M. and Chizzonite, R. (1992) "Regulation of Human Cytolytic Lymphocyte Responses by Interleukin-12", *Cell. Immunol.* 143: 127-142;
58. Paul, W.E. (1989) *Fundamental Immunology*, Raven Press, pp. 628-629, 647-651;
59. Rose, N.R. et al. (1986) *Manual of Clinical Laboratory Immunology*, American Society for Microbiology, 89-109;
60. Rossi, M. C. and Zetter, B.R. (1992) Selective Stimulation of Prostatic Carcinoma Cell Proliferation by Transferrin, *Proc. Natl. Acad. Sci. USA* 89: 6197-6201;
61. Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, 16.1-16.81;
62. Schneider, C., Owen, M.J., Banville, D. and Williams, J.G.

- (1984) Primary Structure of Human Transferrin Receptor Deduced from the mRNA sequence, *Nature* 311: 675-678;
63. Stites, D.P. et al. (1991) *Basic and Clinical Immunology*, Appleton & Lange, 229-251;
  64. Tortora, G.J. et al. (1989) *Microbiology, An Introduction*, Benjamin/Cummings Publishing Co., 423-426, 471;
  65. U.S. Patent No. 5,672,592, issued September 30, 1997 to Paul F. Jackson and Barbara S. Slusher;
  66. U.S. Patent No. 5,795,877, issued August 18, 1998 to Paul F. Jackson et al.;
  67. U.S. Patent No. 5,804,602, issued September 8, 1998 to Barbara S. Slusher et al.;
  68. U.S. Patent No. 5,863,536, issued January 26, 1999 to Paul F. Jackson et al.;
  69. U.S. Patent No. 5,880,112, issued March 9, 1999 to Paul F. Jackson et al.;
  70. U.S. Patent No. 5,902,817, issued May 11, 1999 to Paul F. Jackson et al.;
  71. U.S. Patent No. 5,962,521, issued October 5, 1999 to Paul F. Jackson et al.;
  72. U.S. Patent No. 5,968,915, issued October 19, 1999 to Paul F. Jackson et al.;
  73. U.S. Patent No. 5,981,209, issued November 9, 1999 to Barbara S. Slusher et al.;
  74. U.S. Patent No. 6,011,021, issued January 4, 2000 to Barbara S. Slusher et al.;
  75. U.S. Patent No. 6,017,903, issued January 25, 2000 to Barbara S. Slusher et al.;
  76. U.S. Patent No. 6,025,344, issued February 15, 2000 to Paul F. Jackson et al.;
  77. U.S. Patent No. 6,025,345, issued February 15, 2000 to Paul F. Jackson et al.;
  78. U.S. Patent No. 6,046,180, issued April 4, 2000 to Paul F.



Applicants: Ron S. Israeli et al.  
U.S. Serial No.: 10/614,625  
Filed: July 2, 2003  
Page 9

- Jackson et al.;
79. U.S. Patent No. 6,054,444, issued April 25, 2000 to Paul F. Jackson et al.;
  80. U.S. Patent No. 6,121,252, issued September 19, 2000 to Paul F. Jackson et al.;
  81. U.S. Patent No. 6,271,245, issued August 7, 2001 to Paul F. Jackson et al.;
  82. U.S. Patent No. 6,288,046, issued September 11, 2001 to Paul F. Jackson et al.;
  83. U.S. Patent No. 6,348,464, issued February 19, 2002 to Paul F. Jackson et al.;
  84. U.S. Patent No. 6,372,726, issued April 16, 2002 to Barbara S. Slusher et al.;
  85. U.S. Patent No. 6,384,022, issued May 7, 2002 to Paul F. Jackson and Barbara S. Slusher;
  86. U.S. Patent No. 6,395,718, issued May 28, 2002 to Barbara S. Slusher and Rena Lapidus;
  87. U.S. Patent No. 6,452,044, issued September 17, 2002 to Paul F. Jackson et al.;
  88. U.S. Patent No. 6,458,775, issued October 1, 2002 to Paul F. Jackson et al.;
  89. U.S. Patent No. 6,479,471, issued November 12, 2002 to Paul F. Jackson et al.;
  90. U.S. Patent No. 6,586,623, issued July 1, 2003 to Takashi Tsukamoto et al.;
  91. Barbara S. Slusher and Krystyna Wozniak, U.S. Serial No. 09/866,729, filed May 30, 2001, U.S. Publication No. 20020013295, published January 31, 2002;
  92. Paul F. Jackson et al., U.S. Serial No. 09/866,758, filed May 30, 2001, U.S. Publication No. 20020019430, published February 14, 2002;
  93. Paul F. Jackson et al., U.S. Serial No. 09/880,861, filed June 15, 2001, U.S. Publication No. 20010044459, published

Applicants: Ron S. Israeli et al.  
U.S. Serial No.: 10/614,625  
Filed: July 2, 2003  
Page 10

November 22, 2001;

94. Takashi Tsukamoto et al., U.S. Serial No. 10/046,917, filed January 17, 2002, U.S. Publication No. 20030105088, published June 5, 2003;
95. Barbara S. Slusher et al., U.S. Serial No. 10/056,079, filed January 28, 2002, U.S. Publication No. 20020151503, published October 17, 2002;
96. Barbara S. Slusher et al., U.S. Serial No. 10/119,828, filed April 11, 2002, U.S. Publication No. 20030064912, published April 13, 2003;
97. Paul F. Jackson et al., U.S. Serial No. 10/164,553, filed June 10, 2002, U.S. Publication No. 20030083374, published May 1, 2003;
98. Barbara S. Slusher et al., U.S. Serial No. 10/209,011, filed August 1, 2002, U.S. Publication No. 20030017965, published January 23, 2003;
99. Takashi Tsukamoto et al., U.S. Serial No. 10/431,462, filed May 8, 2003, U.S. Publication No. 20030216468, published November 20, 2003;
100. U.S. Patent No. 5,773,292, issued June 30, 1998 to Neil H. Bander;
101. U.S. Patent No. 6,649,163, issued November 18, 2003 to Neil H. Bander;
102. Neil H. Bander, U.S. Serial No. 09/929,546, filed August 13, 2001, U.S. Publication No. 20030031673, published February 13, 2003;
103. Neil H. Bander, U.S. Serial No. 09/929,665, filed August 13, 2001, U.S. Publication No. 20030003101, published January 2, 2003;
104. Neil H. Bander, U.S. Serial No. 09/929,543, filed August 13, 2001, U.S. Publication No. 20020015704, published February 7, 2002;
105. Gerald P. Murphy et al., U.S. Serial No. 10/428,360, filed

Applicants: Ron S. Israeli et al.  
U.S. Serial No.: 10/614,625  
Filed: July 2, 2003  
Page 11

- May 1, 2003, U.S. Publication No. 20040024188, published February 5, 2004;
106. David M. Nanus et al., U.S. Serial No. 10/160,994, filed May 30, 2002, U.S. Publication No. 20030007974, published January 9, 2003;
  107. PCT International Application No. PCT/US02/17298, filed May 30, 2002, International Publication No. WO 02/096460 A1, published December 5, 2002;
  108. PCT International Application No. PCT/US02/17068, filed May 30, 2002, International Publication No. WO 02/098897 A2, published December 12, 2002;
  109. U.S. Patent No. 5,935,818, issued August 10, 1999 to Ron S. Israeli et al.;
  110. U.S. Patent No. 6,569,432 B1, issued May 27, 2003 to Ron S. Israeli et al.;
  111. Pending claims in Ron S. Israeli et al., U.S. Serial No. 08/403,803, filed March 17, 1995;
  112. Pending claims in Ron S. Israeli et al., U.S. Serial No. 08/466,381, filed June 6, 1995;
  113. Pending claims in Ron S. Israeli et al., U.S. Serial No. 08/470,735, filed June 6, 1995;
  114. Pending claims in Ron S. Israeli et al., U.S. Serial No. 09/724,026, filed November 28, 2000;
  115. Pending claims in Ron S. Israeli et al., U.S. Serial No. 09/990,595, filed November 21, 2001;
  116. Pending claims in Ron S. Israeli et al., U.S. Serial No. 08/481,916, filed June 7, 1995;
  117. Pending claims in Ron S. Israeli et al., U.S. Serial No. 10/012,169, filed October 24, 2001;
  118. Pending claims in Ron S. Israeli et al., U.S. Serial No. 08/894,583, filed February 23, 1998;
  119. Pending claims in Ron S. Israeli et al., U.S. Serial No. 10/751,346, filed January 2, 2004;

Applicants: Ron S. Israeli et al.  
U.S. Serial No.: 10/614,625  
Filed: July 2, 2003  
Page 12

120. PCT International Application No. PCT/US96/02424, filed February 23, 1996, International Publication No. WO 96/26272, published August 29, 1996;
121. Pending claims in Ron S. Israeli et al., U.S. Serial No. 10/443,694, filed May 21, 2003, U.S. Publication No. 20040001846, published January 1, 2004;
122. Neil H. Bander, U.S. Serial No. 09/357,704, filed July 20, 1999;
123. Neil H. Bander, U.S. Serial No. 09/357,707, filed July 20, 1999;
124. Neil H. Bander, U.S. Serial No. 09/357,708, filed July 20, 1999;
125. Neil H. Bander, U.S. Serial No. 09/357,709, filed July 20, 1999;
126. Neil H. Bander, U.S. Serial No. 09/357,710, filed July 20, 1999;
127. Gerald P. Murphy et al., U.S. Serial No. 09/561,462, filed April 28, 2000;
128. Gerald P. Murphy et al., U.S. Serial No. 09/561,502, filed April 28, 2000; and
129. Gerald P. Murphy et al., U.S. Serial No. 09/724,630, filed November 28, 2000.

The Examiner is respectfully requested to make these references of record in the present application by initialing and dating the PTO 1449 form provided as **Exhibit A**, and returning a copy of the executed form to applicants' representatives with the next Communication concerning this application.

The subject application is a continuation-in-part of and claims the priority of United States Application Serial No. 10/433,694, filed May 21, 2003, which is a continuation of U.S. Serial No. 08/705,477, filed August 29, 1996 and issued May 27, 2003 as U.S.

Applicants: Ron S. Israeli et al.  
U.S. Serial No.: 10/614,625  
Filed: July 2, 2003  
Page 13

Patent No. 6,569,432. U.S. Patent No. 6,569,432 is a continuation-in-part and claims priority of International Application No. PCT/US96/02424, filed February 23, 1996, which is a continuation-in-part of and claims priority of U.S. Serial Nos. 08/466,381 and 08/470,735, both filed June 6, 1995.

All of the above-listed references for which copies are available to applicants have previously been submitted to, or cited by, the U.S. Patent and Trademark Office in connection with applications relied upon by the present application for an earlier effective filing date. Specifically, the following references were submitted to or cited by the Patent Office in connection with U.S. Serial No. 08/466,381: references 1-42 were submitted in an Information Disclosure Statement filed July 11, 1997; references 43 and 44 were submitted in a Supplemental Information Disclosure Statement filed March 20, 2000; references 45-48 were submitted in a Supplemental Information Disclosure Statement filed October 20, 2000; references 49 and 50 were submitted in a Supplemental Information Disclosure Statement filed January 19, 2001; reference 51 was submitted in a Supplemental Information Disclosure Statement filed May 7, 2002; and references 52-54 were cited by the Patent Office in an Office Action issued on May 12, 1998. The above-listed references 55-64 were submitted to the Patent Office in a Supplemental Information Disclosure Statement filed on June 27, 2001, in connection with U.S. Serial No. 08/470,735. The above-listed references 65-120 were submitted to the Patent Office in a Supplemental Information Disclosure Statement filed on March 5, 2004, in connection with U.S. Serial No. 10/443,694. The above-listed reference 121 was submitted to the Patent Office as Exhibit 53 in a Supplemental Information Disclosure Statement filed on March 5, 2004, in connection with U.S. Serial No. 08/466,381. Accordingly, pursuant to 37 C.F.R. §1.98(d), copies of the above-identified references are not

Applicants: Ron S. Israeli et al.  
U.S. Serial No.: 10/614,625  
Filed: July 2, 2003  
Page 14

provided herein since they were previously submitted to, or cited by, the Patent Office in applications relied upon for an earlier effective filing date under 35 U.S.C. §120.

References 122-126 are applications claiming priority of U.S. Patent No. 6,107,090 to Bander (filed April 9, 1997 under U.S. Serial No. 08/836,682 and issued August 22, 2000). The Bander '090 patent is cited as reference 46 in the present Supplemental Information Disclosure Statement. Copies of references 122-126 are not provided as they are unpublished and unavailable to applicants. However, they are understood to be available to the Examiner for his review and consideration.

References 127-129 are applications claiming priority of U.S. Patent No. 6,150,508 to Murphy et al. (filed March 18, 1998 under Serial No. 09/044,668 and issued November 21, 2000). The Murphy et al. '508 patent is cited as reference 50 in the present Supplemental Information Disclosure Statement. Copies of references 127-129 are not provided as they are unpublished and unavailable to applicants. However, they are understood to be available to the Examiner for his review and consideration.

Further to the above, applicants direct the Examiner's attention to the article by Su et al. entitled "Alternatively Spliced Variants of Prostate-specific Membrane Antigen RNA: Ratio of Expression as a Potential Measurement of Progression" (Cancer Research 55: 1441-1443, 1995; reference 51, above), dealing with a splice variant of prostate specific membrane antigen. The first named author of the subject paper, Dr. Sai L. Su, has alleged that he was a co-inventor of claims directed to a splice variant of prostate specific membrane antigen contained in U.S. Patent No. 5,935,818 to Israeli et al. which issued August 10, 1999 and which is assigned to the Assignee of the present case.


Applicants: Ron S. Israeli et al.  
U.S. Serial No.: 10/614,625  
Filed: July 2, 2003  
Page 15

The subject matter of the claims of U.S. Patent No. 5,935,818 is not, however, the subject matter claimed in the present application. Applicants' representatives are investigating the claim raised by Dr. Su.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone either of them at the number provided below.

Pursuant to 37 C.F.R. §1.97(b)(3), no fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:  
Commissioner for Patents  
P.O. Box 1450, Alexandria  
VA 22313-1450

 3-26-04

John P. White  
Reg. No. 28,678  
Mark A. Farley  
Reg. No. 33,170

Date

John P. White  
Registration No. 28,678  
Mark A. Farley  
Registration No. 33,170  
Attorneys for Applicant(s)  
Cooper & Dunham, LLP  
1185 Avenue of the  
Americas  
New York, New York 10036  
(212) 278-0400



<b>Form PTO-1449</b> <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		<b>Atty. Docket No.</b> 41426-GC /JPW/MAF/AJD		<b>Serial No.</b> 10/614,625										
		<b>Applicant(s)</b> Ron S. Israeli et al.												
		<b>Filing Date</b> July 2, 2003		<b>Art Unit</b>										
<b>U.S. PATENT DOCUMENTS</b>														
<b>Examiner Initials</b>		<b>Document Number</b>							<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>	
		4	5	5	4	1	0	1	11/19/85	Hopp				
		5	1	6	2	5	0	4	11/10/92	Horoszewicz				
		5	5	3	8	8	6	6	07/23/96	Israeli et al.				
		5	1	5	3	1	1	8	10/06/92	Wright et al.				
		5	8	5	2	1	6	7	12/22/98	Kay et al.				
		5	9	3	9	2	5	8	08/17/99	Croce et al.				
		6	1	0	7	0	9	0	08/22/00	Bander				
		6	1	3	6	3	1	1	10/24/00	Bander				
		6	1	5	0	5	0	8	11/21/00	Murphy et al.				
<b>FOREIGN PATENT DOCUMENTS</b>														
		<b>Document Number</b>							<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation</b>	
													<b>Yes</b>	<b>No</b>
		9	4	0	9	8	2	0	05/11/94	PCT				
		9	7	3	5	6	1	6	10/02/97	PCT				
		9	9	4	7	5	5	4	09/23/99	PCT				
		02	0	9	6	4	6	0	12/05/02	PCT				
		02	0	9	8	8	9	7	12/12/02	PCT				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
		Abdel-Nabi, H., Wright, G.L., Gulfo, J.V., Petrylak, D.P., Neal, C.E. et al. (1992) Monoclonal Antibodies and Radioimmunoconjugates in the Diagnosis and Treatment of Prostate Cancer, <i>Semin. Urol.</i> 10: 45-54;												
		Axelrod, H.R. et al. (1992) Preclinical results and human immunohistochemical studies with <sup>90</sup> Y-CYT-356. A new prostate cancer therapeutic agent, <i>Abstract 596. AUA 87th Annual Meeting</i> , May 10-14, 1992, Washington, D.C.;												
		Carter, B.H. and Coffey, D.S. (1990) The Prostate: An Increasing Medical Problem, <i>The Prostate</i> 16: 39-48;												
		Chang, C.S., Kokontis, J. and Liao, S.T. (1988) Structural Analysis of Complementary DNA and Amino Acid Sequences of Human and Rat Androgen Receptors, <i>Proc. Natl. Acad. Sci. USA</i> 85: 7211-7215;												
<b>EXAMINER</b>										<b>DATE CONSIDERED</b>				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

NO received  
that Doc



<b>Form PTO-1449</b>  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		<b>Atty. Docket No.</b> 41426-GC /JPW/MAF/AJD		<b>Serial No.</b> 10/614,625									
		<b>Applicant(s)</b> Ron S. Israeli et al.											
		<b>Filing Date</b> July 2, 2003		<b>Art Unit</b>									
<b>U.S. PATENT DOCUMENTS</b>													
<b>Examiner Initials</b>		<b>Document Number</b>			<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>				
		5	6	7	2	5	9	2	09/30/97	Jackson et al.			
		5	7	9	5	8	7	7	08/18/98	Jackson et al.			
		5	8	0	4	6	0	2	09/08/98	Slusher et al.			
		5	8	6	3	5	3	6	01/26/99	Jackson et al.			
		5	8	8	0	1	1	2	03/09/99	Jackson et al.			
		5	9	0	2	8	1	7	05/11/99	Jackson et al.			
		5	9	6	2	5	2	1	10/05/99	Jackson et al.			
		5	9	6	8	9	1	5	10/19/99	Jackson et al.			
		5	9	8	1	2	0	9	11/09/99	Slusher et al.			
<b>FOREIGN PATENT DOCUMENTS</b>													
		<b>Document Number</b>			<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation</b>				
										<b>Yes</b>	<b>No</b>		
		9	6	2	6	2	7	2	08/29/96	PCT			
		0	1	7	3	9	5	1	12/03/86	EPO			
		0	1	7	3	9	5	1	12/03/86	EPO	X		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>													
		Corr, J.G. et al. (1994) Prostate Specific Membrane Antigen (PSM) Expression in Orthotopically Implanted Human Prostate Cancer Cells in Nude Mice Slows Tumor Growth and Metastatic Potential, <i>J. Urol.</i> 151: 492A;											
		Culver, K.W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E.H. and Blaese, R.M. (1992) In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors, <i>Science</i> 256: 1150-1552;											
		Decensi, A., Guarneri, D., Paoletti, M.C., Lalanne, J.M., Merlo, F. and Boccardo, F. (1991) Phase II Study of the Pure Non-steroidal Antiandrogen Nilutamide in Prostatic Cancer, <i>Eur. J. Cancer</i> 27: 1100-1104;											
		Faber, P.W., van Rooij, H.C., van der Korput, H.A., Baarends, W.M., Brinkmann, A.O., Grootegoed, J.A. and Trapman, J. (1991) Characterization of the Human Androgen Transcription Unit, <i>J. Biol. Chem.</i> 266: 10743-10749;											
<b>EXAMINER</b>						<b>DATE CONSIDERED</b>							
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 41426-GC /JPW/MAF/AJD		Serial No. 10/614,625								
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Applicant(s) Ron S. Israeli et al.										
				Filing Date July 2, 2003		Art Unit								
<b>U.S. PATENT DOCUMENTS</b>														
Examiner Initials		Document Number							Date	Name	Class	Subclass	Filing Date If Appropriate	
		6	0	1	1	0	2	1	01/04/00	Slusher et al.				
		6	0	1	7	9	0	3	01/25/00	Slusher et al.				
		6	0	2	5	3	4	4	02/15/00	Jackson et al.				
		6	0	2	5	3	4	5	02/15/00	Jackson et al.				
		6	0	4	6	1	8	0	04/04/00	Jackson et al.				
		6	0	5	4	4	4	4	04/25/00	Jackson et al.				
		6	1	2	1	2	5	2	09/19/00	Jackson et al.				
		6	2	7	1	2	4	5	08/07/01	Jackson et al.				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
		Feng, Q. et al. (1991) Purification and Biochemical Characterization of the 7E11-C5 Prostate Carcinoma-Associated Antigen, <i>Proc. Am. Assoc. Cancer Res.</i> 32: 239;												
		Fey, M.F., Kulozik, A.E., Hansen-Hagge, T.E. and Tobler, A. (1991) The Polymerase Chain Reaction: A New Tool for the Detection of Minimal Residual Disease in Haematological Malignancies, <i>Eur. J. Cancer</i> 27: 89-94;												
		Henttu, P. and Vihko, P. (1989) cDNA Coding for the Entire Human Prostate Specific Antigen Shows High Homologies to the Human Tissue Kallikrein Genes, <i>Biochem. Biophys. Res. Commun.</i> 160: 903-910;												
		Horoszewicz, J.S., Kawinski, E. and Murphy, G.P. (1987) Monoclonal Antibodies to a New Antigen Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients, <i>AntiCancer Res.</i> 7: 927-936;												
		Huber, B.E., Richards, C.A. and Krenitsky, T.A. (1991) Retroviral-mediated Gene Therapy for the Treatment of Hepatocellular Carcinoma: An Innovative Approach for Cancer Therapy, <i>Proc. Natl. Acad. Sci. USA</i> 88:8039-8043;												
		Israeli, R.S. et al., (1992) Purification and Molecular Cloning of a New Prostate-Specific Antigen, <i>Cancer Res.</i> 33: 356;												
		Israeli, R.S., Powell, C.T., Fair, W.R. and Heston, W.D. (1993) Molecular Cloning of a Complementary DNA Encoding a Prostate-specific Membrane Antigen, <i>Cancer Res.</i> 53: 227-230;												
		Israeli, R.S. et al. (1993) Molecular Cloning and Characterization of a Prostate-Specific Membrane Antigen, <i>J. Urol.</i> 149: 471A;												
		Israeli, R.S. et al. (1993) Characterization of the Prostate-Specific Membrane Antigen (PSM), <i>Proc. Am. Assoc. Cancer Res.</i> 34: 255;												
		Israeli, R.S., Powell, C.T., Corr, J.G., Fair, W.R. and Heston, W.D. (1994) Expression of the Prostate Specific Membrane Antigen, <i>Cancer Res.</i> 54: 1807-1811;												
		Israeli, R.S., Miller, W.H. Jr., Su, S.L., Powell, C.T., Fair, W.R. et al. (1994) Sensitive Nested Reverse Transcription Polymerase Chain Reaction Detection of Circulating Prostatic Tumor Cells: Comparison of Prostate-specific Membrane Antigen and Prostate-												

		specific Antigen-based Assays, Cancer Research 54: 6306-6310;
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>		<b>Atty. Docket No.</b> 41426-GC /JPW/MAF/AJD		<b>Serial No.</b> 10/614,625					
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				<b>Applicant(s)</b> Ron S. Israeli et al.							
				<b>Filing Date</b> July 2, 2003		<b>Art Unit</b>					
<b>U.S. PATENT DOCUMENTS</b>											
<b>Examiner Initials</b>		<b>Document Number</b>				<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>	
		6	2	8	8	0	4	6	09/11/01	Jackson et al.	
		6	3	4	8	4	6	4	02/19/02	Jackson et al.	
		6	3	7	2	7	2	6	04/16/02	Slusher et al.	
		6	3	8	4	0	2	2	05/07/02	Jackson et al.	
		6	3	9	5	7	1	8	05/28/02	Slusher et al.	
		6	4	5	2	0	4	4	09/17/02	Jackson et al.	
		6	4	5	8	7	7	5	10/01/02	Jackson et al.	
		6	4	7	9	4	7	1	11/12/02	Jackson et al.	
		6	5	8	6	6	2	3	07/01/03	Tsukamoto et al.	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>											
		Israeli, R.S. et al. (1994) Localization of the Prostate Specific Membrane Antigen (PSM) to the Putative Metastasis-Suppressor Region on Human Chromosome 11, <i>J. Urol.</i> 151: 252A;									
		Israeli, R.S. et al., (1994) Sensitive Detection of Prostatic Hematogenous Micro-Metastases Using Prostate Specific Antigen (PSA) And Prostate Specific Membrane Antigen (PSM) Derived Primers in the Polymerase Chain Reaction (PCR), <i>J. Urol.</i> 151: 373A;									
		Israeli, R.S. et al. (1994) Localization of the Prostate Specific Membrane Antigen (PSM) to the Putative Metastasis-Suppressor Region on Human Chromosome 11, <i>Proc. Am. Assoc. Cancer Res.</i> 35: 271;									
		Keer, H.N., Kozlowski, J.M., Tsai, Y.C., Lee, C., McEwan, R.N. and Grayhack, J.T. (1990) Elevated Transferrin Receptor Content in Human Prostate Cancer Cell Lines Assessed In Vitro and In Vivo, <i>J. Urol.</i> 143: 381-385;									
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>									
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											

<b>Form PTO-1449</b>  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		<b>Atty. Docket No.</b> 41426-GC /JPW/MAF/AJD	<b>Serial No.</b> 10/614,625				
		<b>Applicant(s)</b> Ron S. Israeli et al.					
		<b>Filing Date</b> July 2, 2003	<b>Art Unit</b>				
<b>U.S. PATENT DOCUMENTS</b>							
<b>Examiner Initials</b>		<b>Document Number</b>	<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>
		2 0 0 2 / 0 0 1 3 2 9 5	01/31/02	Slusher et al.			05/30/01
		2 0 0 2 / 0 0 1 9 4 3 0	02/14/02	Jackson et al.			05/30/01
		2 0 0 2 / 0 0 4 4 4 5 9	11/22/01	Jackson et al.			06/15/01
		2 0 0 3 / 0 1 0 5 0 8 8	06/05/03	Tsukamoto et al.			01/17/02
		2 0 0 2 / 0 1 5 1 5 0 3	10/17/02	Slusher et al.			01/28/02
		2 0 0 3 / 0 0 6 4 9 1 2	04/13/03	Slusher et al.			04/11/02
		2 0 0 3 / 0 0 8 3 3 7 4	05/01/03	Jackson et al.			06/10/02
		2 0 0 3 / 0 0 1 7 9 6 5	01/23/03	Slusher et al.			08/01/02
		2 0 0 3 / 0 2 1 6 4 6 8	11/20/03	Tsukamoto et al.			05/08/03
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
		Lopes, A. D. et al. (1993) Immunohistochemical and Pharmacokinetic Characterization of the Site-specific Immunoconjugate CYT-356 Derived from Antiprostate Monoclonal Antibody, <i>Cancer Res.</i> 50: 6423-6429;					
		Lubahn, D.B., Brown, T.R., Simental, J.A., Higgs, H.N., Migeon, C.J., Wilson, E.M. and French, F.S. (1989) Sequence of the Intron/exon Junctions of the Coding Region of the Human Androgen Receptor Gene and Identification of a Point Mutation in a family with Complete Androgen Insensitivity, <i>Proc. Natl. Acad. Sci. USA</i> 86: 9534-9538;					
		Lundwall, A. and Lilja, H. (1987) Molecular Cloning of Human Prostate Specific Antigen cDNA, <i>FEBS Lettr.</i> 214: 317-322;					
		Mukhopadhyay, T., Tainsky, M., Cavender, A.C. and Roth, J.A. (1991) Specific Inhibition of K-ras Expression and Tumorigenicity of Lung Cancer Cells by Antisense RNA <sup>1</sup> , <i>Cancer Res.</i> 51: 1744-1748;					
		Riegman, P.H.J. et al. (1989) The Prostate-Specific Antigen Gene and the Human Glandular Kallikrein-1 Gene are Tandemly Located on Chromosome 19, <i>FEBS Lettr.</i> 247: 123-126;					
		Sharief, F.S., Lee, H., Leuderman, M.M., Lundwall, A., Deaven, L.L., Lee, C.L. and Li, S.S. (1989) Human prostatic acid phosphatase: cDNA cloning, gene mapping and protein sequence homology with lysosomal acid phosphatase. <i>Biochem. Biophys. Res. Commun.</i> 160: 79-86;					
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>		<b>Atty. Docket No.</b> 41426-GC /JPW/MAF/AJD		<b>Serial No.</b> 10/614,625							
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				<b>Applicant(s)</b> Ron S. Israeli et al.									
				<b>Filing Date</b> July 2, 2003		<b>Art Unit</b>							
<b>U.S. PATENT DOCUMENTS</b>													
Examiner Initials		Document Number						Date	Name	Class	Subclass	Filing Date If Appropriate	
		5	7	7	3	2	9	2	06/30/98	Bander			
		6	6	4	9	1	6	3	11/18/03	Bander			
		2 0 0 3 / 0 0 3 1 6 7 3						02/13/03	Bander			08/13/01	
		2 0 0 3 / 0 0 0 3 1 0 1						01/02/03	Bander			08/13/01	
		2 0 0 2 / 0 0 1 5 7 0 4						02/07/02	Bander			08/13/01	
		2 0 0 4 / 0 0 2 4 1 8 8						02/05/04	Murphy et al.			05/01/03	
		2 0 0 3 / 0 0 0 7 9 7 4						01/09/03	Nanus et al.			05/30/02	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>													
		Solin, T., Kontturi, M., Pohlmann, R. and Vihko, P. (1990) Gene Expression and Prostate Specificity of Human Prostatic Acid Phosphatase (PAP): Evaluation By RNA Blot Analyses, <i>Biochem. Biophys. Acta</i> 1048: 72-77;											
		Su, S.L., et al. (1994) Sensitive Detection of Prostatic Hematogenous Micrometastases Using Prostate Specific Antigen (PSA) and Prostate Specific Membrane Antigen (PSM) Derived Parameters in the Polymerase Chain Reaction, <i>Proc. Am. Assoc. Cancer Res.</i> 35: 271;											
		Troyer, John K. (1994) Biochemical Characterization and Mapping of the 7E11-C5.3 Epitope of the Prostate Specific Membrane Antigen (PSMA), <i>Basic and Clinical Aspects of Prostate Cancer: Abstract C38</i> ;											
		Vihko, P., Virkkunen, P., Henttu, P., Roiko, K., Solin, T. and Huhtala, M.L. (1988) Molecular Cloning and Sequence Analysis of cDNA Encoding Human Prostatic Acid Phosphatase, <i>FEBS Lett.</i> 236: 275-281;											
		Vile, R.G. and Hart, I.R. (1993) In Vitro and In Vivo Targeting of Gene Expression to Melanoma Cells, <i>Cancer Res.</i> 53: 962-967;											
		Waibel, R. et al. (1990) Therapy of Small Cell Lung Cancer Xenografts in a Nude Mouse model: Evaluation of Radioimmunotherapy and Immunotoxin Therapy, <i>Antibody Immunoconjugates and Radiopharmaceuticals</i> 34: 54;											
		Watt, K.W.K. et al. (1986) Human Prostate-Specific Antigen: Structural and Functional Similarity with Serine Proteases, <i>Proc. Natl. Acad. Sci. USA</i> 83: 3166-3170;											
		Wright, Jr., G.L., Feng, Q., Beckett, M.L., Lopes, D. and Gilman, S.C. (1990) Characterization of a new prostate carcinoma-associated marker: 7E11-C5. <i>Antibody, Immunoconjugates and Radiopharmaceuticals</i> 3: 89 (Abstract 193);											
<b>EXAMINER</b>								<b>DATE CONSIDERED</b>					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

<b>Form PTO-1449</b>  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		<b>Atty. Docket No.</b> 41426-GC /JPW/MAF/AJD  <b>Applicant(s)</b> Ron S. Israeli et al.  <b>Filing Date</b> July 2, 2003		<b>Serial No.</b> 10/614,625   <b>Art Unit</b>									
<b>U.S. PATENT DOCUMENTS</b>													
<b>Examiner Initials</b>		<b>Document Number</b>			<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>				
		5	9	3	5	8	1	8	08/10/99	Israeli et al.			
		6	5	6	9	4	3	2	05/27/03	Israeli et al.			
		08	4	0	3	8	0	3		Israeli et al.			03/17/95
		08	4	6	6	3	8	1		Israeli et al.			06/06/95
		08	4	7	0	7	3	5		Israeli et al.			06/06/95
		09	7	2	4	0	2	6		Israeli et al.			11/28/00
		09	9	9	0	5	9	5		Israeli et al.			11/21/01
		08	4	8	1	9	1	6		Israeli et al.			06/07/95
		10	0	1	2	1	6	9		Israeli et al.			10/24/01
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>													
		Young, R.A. and Davis, R.W. (1983) Efficient Isolation of Genes by Using Antibody Probes, <i>Proc. Natl. Acad. Sci. USA</i> 80: 1194-1198;											
		Su, S.L., Huang, I.P., Fair, W.R., Powell, C.T. and Heston, W.D. (1995) <i>Cancer Res.</i> , 55: 1441-1443;											
		Bowie, J.U., Reidhaar-Olson, J.F., Lim, W.A. and Sauer, R.T. (1990) Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions, <i>Science</i> 147: 1306-1310;											
		Kumar, V., Urban, J.L., Horvath, S.J. and Hood, L. (1990) Amino Acid Variations at a Single Residue in an Autoimmune Peptide Profoundly Affect Its Properties: T-Cell Activation, Major Histocompatibility Complex Binding, and Ability to Block Experimental Allergic Encephalomyelitis, <i>Proc. Natl. Acad. Sci. USA</i> 87: 1337-1341;											
		Lazar, E., Watanabe, S., Dalton, S. and Sporn, M.B. (1988) Transforming Growth Factor $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, <i>Mol. Cell Biol.</i> 8: 1247-1252;											
		Gately, M.K., Wolitzky, A.G., Quinn, P.M. and Chizzonite, R. (1992) "Regulation of Human Cytolytic Lymphocyte Responses by Interleukin-12", <i>Cell. Immunol.</i> 143: 127-142;											
		Paul, W.E. (1989) <i>Fundamental Immunology</i> , Raven Press, pp. 628-629, 647-651; Paul, W.E. (1989) <i>Fundamental Immunology</i> , Raven Press, pp. 628-629, 647-651;											
<b>EXAMINER</b>						<b>DATE CONSIDERED</b>							
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

<b>Form PTO-1449</b>  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		<b>Atty. Docket No.</b> 41426-GC /JPW/MAF/AJD		<b>Serial No.</b> 10/614,625		
		<b>Applicant(s)</b> Ron S. Israeli et al.				
		<b>Filing Date</b> July 2, 2003		<b>Art Unit</b>		
<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	0 8 8 9 4 5 8 3		Israeli et al.			02/13/98
	10 7 5 1 3 4 6		Israeli et al.			02/02/04
	2 0 0 4 / 0 0 0 1 8 4 6	01/01/04	Israeli et al.			05/21/03
	0 9 3 5 7 7 0 4		Bander			07/20/99
	0 9 3 5 7 7 0 7		Bander			07/20/99
	0 9 3 5 7 7 0 8		Bander			07/20/99
	0 9 3 5 7 7 0 9		Bander			07/20/99
	0 9 3 5 7 7 1 0		Bander			07/20/99
	0 9 5 6 1 4 6 2		Murphy et al			04/28/00
	0 9 5 6 1 5 0 2		Murphy et al			04/28/00
	0 9 7 2 4 6 3 0		Murphy et al			11/28/00
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
	Rose, N.R. et al. (1986) <i>Manual of Clinical Laboratory Immunology</i> , American Society for Microbiology, 89-109;					
	Rossi, M. C. and Zetter, B.R. (1992) Selective Stimulation of Prostatic Carcinoma Cell Proliferation by Transferrin, <i>Proc. Natl. Acad. Sci. USA</i> 89: 6197-6201;					
	Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) <i>Molecular Cloning, A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press, 16.1-16.81;					
	Schneider, C., Owen, M.J., Banville, D. and Williams, J.G. (1984) Primary Structure of Human Transferrin Receptor Deduced from the mRNA sequence, <i>Nature</i> 311: 675-678;					
	Stites, D.P. et al. (1991) <i>Basic and Clinical Immunology</i> , Appleton & Lange, 229-251; and					
	Tortora, G.J. et al. (1989) <i>Microbiology, An Introduction</i> , Benjamin/Cummings Publishing Co., 423-426, 471;					
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						